photo of jonathan riess taken from health.ucdavis.edu
Aug 28, 2024, 19:52
Impact of baseline positive vs negative plasma Circulating tumor DNA for Estimated glomerular filtration rate in the FLAURA2 trial by Jonathan Riess
David Gandara, Co-Director-Center for Experimental Therapeutics, shared a post on X:
“At Cal Cancer Consortium conference, Jonathan Riess shows impact of baseline positive vs negative plasma Circulating tumor DNA for Estimated glomerular filtration rate in the FLAURA2 trial.
Addition of chemo to Osi mainly benefitting those with positive Circulating tumor DNA .
Food for thought!”
Source: David Gandara/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 09:54
Feb 21, 2025, 09:45
Feb 21, 2025, 09:35
Feb 21, 2025, 09:18
Feb 21, 2025, 09:07
Feb 21, 2025, 09:00
Feb 21, 2025, 08:19
Feb 21, 2025, 06:20